Vemurafenib-analogue is a potent BRAF inhibitor and the isomer of Vemurafenib. Vemurafenib, formerly known as PLX4032, RG7204 or RO5185426, is an orally bioavailable, ATP-competitive, small-molecule inhibitor of BRAF(V600E) kinase with potential antineoplastic activity. Vemurafenib received FDA approval for the treatment of late-stage melanoma on August 17, 2011. References: Yu L, Gao LX, Ma XQ, Hu FX, Li CM, Lu Z. Involvement of superoxide and nitric oxide in BRAF(V600E) inhibitor PLX4032-induced growth inhibition of melanoma cells. Integr Biol (Camb). 2014 Dec;6(12):1211-7. doi: 10.1039/c4ib00170b. Epub 2014 Nov 3. PubMed PMID: 25363644.

纯度：≥98%

CAS：918505-61-0